KEY POINTS
Prospectively collected data on demographics, complications, and mortality are described for 4,899 U.S. men with severe hemophilia.
Analyzing multiple birth cohorts of U.S. men with severe and mild hemophilia demonstrates ongoing morbidity in need of surveillance.
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ABSTRACT
The availability of longitudinal data collected prospectively from 1998 to 2011 at federally funded United States hemophilia treatment centers (U.S. HTCs) provided an opportunity to construct a descriptive analysis of how outcomes of men with severe hemophilia have been altered by the incremental advances and setbacks in hemophilia care in the last 50 years in the U.S. This surveillance collaboration with the U.S. Centers for Disease Control and Prevention assembled the largest uniformly examined population with severe hemophilia (n = 4,899 men with severe factor VIII and IX deficiency). To address the heterogeneity of this population, four successive birth cohorts, differentially affected by "eras" of hemophilia care, were examined separately in regards to demographics, complications of hemophilia and its treatment, and mortality. Severely affected men in each birth cohort were compared also to the corresponding mild hemophilia birth cohorts (n = 2587 men total) to control for outcomes that might be attributable to aging and environment independent of severely defective hemostasis. The analysis demonstrates improving access to standard of care therapy, correlating the proportion of men on prophylactic factor replacement and reduced bleeding frequency for the youngest men. Frequent bleeding persisted in one third to one half of men across all ages, however, and the disability gap between severe and mild hemophilia did not narrow. The greatest cause of death was liver failure but attempted anti-hepatitis C virus therapy and cure were low. The study suggests a continued need for national surveillance to monitor and inform hemophilia interventions and outcomes.
INTRODUCTION
Over approximately the last 5 decades, the experience of men and boys with hemophilia has been characterized by remarkable progress in drug therapies and the delivery of multidisciplinary care 1 , interrupted by tragic setbacks from transfusiontransmitted infections ( Figure 1 ). 2 The oldest generation of men with hemophilia in the U.S. experienced childhood with no or little availability of clotting factor replacement. contamination of plasma-derived factor concentrates drove the rapid development and licensure of recombinant factor products in the 1990s.
In 1975, the US Congress appropriated funds to create a national network of Hemophilia Diagnostic and Treatment Centers, which grew into the current US hemophilia treatment center network (HTCN). 3 The US Centers for Disease Control and Prevention (CDC) partnered with this network in the late 1980's to implement strategies to prevent the spread of HIV infection, and subsequently expanded surveillance and prevention programs implemented through the HTCs to address additional complications of bleeding disorders. 4 In 1998 this CDC/HTCN collaboration launched a national public health surveillance designated the Universal Data Collection (UDC). 5 Modern hemophilia care in the U.S. is characterized by an adequate supply of pathogen-free clotting factor concentrate infused at home, either prophylactically or on-demand, with the majority of the hemophilia population receiving care through a network of approximately 130
For personal use only. on March 16, 2016 . by guest www.bloodjournal.org From regionally organized Hemophilia Treatment Centers (HTCs) practicing a team-based integrated services model. 6 Incremental improvements in the standards and access to care as well as setbacks related to treatment complications have naturally created "eras" of care affecting successive birth cohorts of men with severe hemophilia. The availability of longitudinal data collected by the UDC on 4899 men with severe factor VIII and IX deficiency provided an opportunity to construct a descriptive analysis of how outcomes have been altered by the incremental advances and setbacks in hemophilia care in the last 50 years in the U.S.
METHODS

Data Collection
Staff at 130 HTCs (>95% of the US HTC Network) used uniform data collection forms to register and annually monitor patients in the UDC database from May 1998 to September 2011. Institutional Review Boards at CDC and all participating institutions approved the study. All participants gave informed consent. Data for this analysis from the initial registration visit included month and year of birth, self-reported race/ethnicity, age at diagnosis, baseline factor activity, and date of first HTC visit. Deaths (including cause) were reported using a standardized mortality form during the entire study period.
All other data came from the most recent HTC visit in which UDC forms were completed. Adults (> 18 years of age) with physician-diagnosed mild or severe hemophilia were used for this descriptive analysis.
For personal use only. on March 16, 2016 . by guest www.bloodjournal.org From Hemophilia severity was defined based on the plasma level of baseline factor activity recorded at registration with severe having levels of <1% of normal and mild having levels of >5% -50% (note that only 2% of men had levels reported between 40 and 50%, an area of unresolved controversy in the definition of mild hemophilia). 7 Endpoints that reflect access to care included age at diagnosis, age at first HTC visit, frequency of HTC utilization, treatment type (episodic versus prophylactic), age at initiation of home infusion, and health insurance type. Data collected to assess potential disease-related complications included self-reported measures of physical function and bleeding complications including target joints, employment status, and body mass index The Eras serve as a framework to evaluate how changes in hemophilia therapies and health care delivery have affected U.S. men with hemophilia within each Era over time.
We chose two frameworks to describe the impact of changes in hemophilia care on the outcomes of men with severe hemophilia. The first examines these men within the experiential birth cohorts delineated Era A through Era D. The second framework attempts to control for the effect of aging on the measured outcomes by comparing outcomes and interventions in men with severe hemophilia in Era A to D to men in the identical aging cohorts having only mild clotting factor deficiency. The second framework acknowledges that differences in demographics, outcomes, and complications for men in each Era can be affected by aging even in the absence of a severe hemostatic defect.
RESULTS
Data from the most recent UDC enrollment were available for 7486 men with mild or severe hemophilia (Table 2 ). Of these, 4899 had severe hemophilia (65.4%) and 2587 had mild hemophilia (34.6%); 6094 men had hemophilia A (81.4%) and 1392 had hemophilia B (18.6%). The younger three Eras contained roughly similar numbers of men with severe hemophilia, and within each birth cohort there were more men with severe hemophilia than mild hemophilia (2.0 -2.9 times more severe hemophilia UDC participants in Eras B-D). Only in the Era of men born before 1958 did men surviving with mild hemophilia outnumber men with severe hemophilia. The mean (median) ages of the men were 59.5 (58), 39.9 (40), 27.2 (28) and 21.9 (21) years in cohorts A-D, respectively.
Demographics and Access to care (Table 2)
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Access to care: Comparing Eras D vs. A, the proportion of men who reported starting home infusion before age six was far greater (over 45% in Era D versus less than 2% in Era A) and those reporting a first HTC visit before age 2 years rose nearly 10-fold. Use of a continuous prophylactic factor regimen was nearly 3-fold greater in the youngest when compared to the oldest adults (approaching 50% in Era D). The Eras differed in regards to insurance, as expected, in line with eligibility criteria for U.S. insurance by age, income, and disability. Participants with severe hemophilia were twice as likely as their mild hemophilia counterparts to have Medicaid, and Medicare. With each progressively younger cohort, the likelihood of having commercial insurance grew. Commercial insurance exceeded 50% only for the severe hemophilia cohort in Era D; whereas commercial insurance exceeded 50% for all mild hemophilia cohorts. Despite this trend, individuals in the two youngest cohorts were also more likely to be uninsured, a pattern that was true regardless of severity of hemophilia. Individuals with mild hemophilia were more likely to be uninsured than individuals with severe hemophilia in each Era.
Disease-related complications (Table 3)
Bleeding and Target Joints: The proportion of participants reporting frequent bleeds decreased with successively younger Era. However, frequent bleeding was prevalent even in the Era treated with the most modern therapies: more than 1 in 3 participants with hemophilia that missed at least 10 days of work or school in the immediately preceding year due to upper or lower extremity joint problems was two or three times that of men of the same age with mild hemophilia, regardless of Era. Disability and Employment: In Era A, nearly half of the participants were disabled and unable to work. In successively younger birth cohorts, fewer men who reported that they were neither employed nor in school indicated that their status was "disabled." Despite this absolute decline in disability, men with severe hemophilia were still about three times as likely to be disabled as their mild hemophilia counterparts regardless of the Era.
Treatment-related complications (Table 4 and Figures 2a, 2b)
For personal use only. on March 16, 2016 . by guest www.bloodjournal.org From Hepatitis B and C and HIV: Since 1992, the UDC population experienced no new infections of HBV, HCV or HIV attributable to plasma-derived or recombinant coagulation factor therapy. Nevertheless, infectious complications remain a critical concern among men with severe hemophilia in all Eras: 95% of men with severe hemophilia in the oldest two Eras, 90% in Era C, and 35% in the youngest Era D have seroconverted to either HBV, HCV, HIV, or a combination of these agents. (Table 4 and Inhibitor Prevalence: Inhibitors occurred with a similar prevalence across all Eras and were consistently more prevalent in men with severe hemophilia (11.5-17.0%) compared with men with mild hemophilia (2.8-3.6%).
Mortality (Table 5)
1
During the study period, a total of 551 deaths were reported. The Era A and B cohorts accounted for 82% of the deaths in the severe hemophilia population and 96% of the deaths in the mild hemophilia population. Although the youngest cohorts reported no liver-related deaths, liver failure was the most commonly reported cause of death overall for both severe (33% of deaths) and mild (26% of deaths) hemophilia cohorts.
Hemophilia (hemorrhage) related deaths accounted for 14.6% of deaths in severe hemophilia and 10.7% of deaths in participants with mild hemophilia across all eras.
DISCUSSION
This analysis examines birth cohorts of U.S. men with severe hemophilia to gauge the impact of changes in hemophilia therapeutics and healthcare delivery over the last half century upon clinical outcomes (access to care, physical and social functioning, and complications including mortality). To our knowledge, this is the largest population of men with severe hemophilia to date studied using a single, uniform data collection tool.
Current access to care for severe hemophilia through the national HTC system was relatively uniform across the birth cohorts: 79-84% of men across the Eras utilized the HTC at least yearly, with the greatest proportion of frequent users being in the eldest era.
The growing composition of minorities in the younger three Eras aligns with the increasing racial/ethnic diversity in the general U.S. population, and provides evidence that minorities have access to the HTC system. In Era D, the proportion of men with severe hemophilia of African American race reached 16.4%, higher than the general 2010
For personal use only. on March 16, 2016 . by guest www.bloodjournal.org From U.S. African American population of 12.6%. Approximately 14% of Era D men were of Hispanic ethnicity, which was comparable to the general U.S. population (16.3%). 8 Home infusion of clotting factor was the prevalent approach to care in 70.3-76.1% of men regardless of Era. Improved access to comprehensive HTC care in more recent decades was evident: Eras C and D contained a majority of men who had their initial HTC visit by their second year of life; 28.5% and 45.7% respectively had started home infusion before the age of six years. The use of continuous prophylactic clotting factor replacement in men with severe hemophilia during 1998-2011 was not the standard of care. However, we did observe an increasing proportion reporting the use of prophylaxis therapy with successively younger Eras, rising to nearly half in Era D.
We observed dramatic differences in the proportion of men with severe hemophilia who reported being disabled or limited in their activity. Fewer men with severe hemophilia used assistive devices and wheelchairs in younger Eras. Nearly 4 out of 5 men with severe hemophilia in Era D were employed or students. Similarly, we observed dramatic declines in HBV infection prevalence starting in Era C, and declines in the prevalence of HCV infection starting in Era D. At the close of the UDC data collection, the prevalence of HIV infection was approximately 1% in Era D men; nearly 2 of 3 men with severe hemophilia in Era D were free of HIV, HBV, and HCV. Mortality was also dramatically lower in Eras C/D than in Eras A/B, and across all Eras, many men with severe hemophilia die with hemophilia rather than from hemophilia related causes.
The two youngest cohorts had the largest proportion of uninsured men. This finding is due to both a larger proportion of minorities compromising the younger Eras and an increase in Whites who were uninsured. Lack of insurance disproportionately For personal use only. on March 16, 2016 . by guest www.bloodjournal.org From affecting minorities in the U.S. is widely documented. 9, 10 The uninsured subset of the hemophilia population is at particularly high risk for long-term morbidity, especially if ready access to clotting factor and to HTC services cannot be maintained. Furthermore, a growing population of men with severe hemophilia who are both uninsured and at greater risk for inhibitor development (due to African American or Hispanic background) [11] [12] [13] [14] is particularly concerning given the increased mortality, the high morbidity and extraordinary financial cost associated with inhibitor development and therapy. 15 Focus on this at-risk subpopulation is warranted to optimize musculoskeletal and other outcomes as these younger Era C and D birth cohorts age.
Despite similarly frequent HTC utilization across all Eras, unacceptably high rates of joint hemorrhages (≥5 hemarthroses per six months) were reported by 42-49% of men in In an effort to control for the effects of aging on physical function, we compared outcomes of men with severe hemophilia to those of men with mild hemophilia within each Era. When observed in this framework, there may be evidence that the effect of frequent bleeds in the younger Eras of men with severe hemophilia may already be associated with disability and loss of physical function. As expected, we observed While the long natural history of HCV infection makes it challenging to estimate the incidence of chronic infection progressing to cirrhosis, for men in the general population the prevalence of the development of cirrhosis at 20 years is at least 20-30% and is potentially accelerated by HIV co-infection. [16] [17] [18] The rate of development of hepatocellular carcinoma is approximately 3-5% per year 17, 19 with a poor prognosis, particularly in patients with cirrhosis and/or poor liver function. 20 Our data demonstrate that from 1998-2011 most deaths predictably occurred in the Era A and Era B cohorts, and in these birth cohorts hepatic failure has eclipsed both HIV and hemorrhage as the leading cause of death. HCV infection was highly prevalent
For personal use only. on March 16, 2016 . by guest www.bloodjournal.org From and the mild hemophilia population was not spared: one third of men with mild hemophilia in Eras A and B had HBV, more than half had HCV and more than one quarter were co-infected. In light of the recent licensure of highly efficacious anti-HCV drugs [21] [22] [23] [24] , the UDC HCV prevalence, morbidity and mortality data provide a strong impetus for hemophilia care providers to evaluate and treat HCV infection so as to address the current greatest contributor to hemophilia mortality. The UDC data presented While the mild hemophilia cohorts of Eras A to D were examined primarily as a comparator group to men with severe hemophilia, to control for the impact of shared aging and environmental complications (independent of frequent hemorrhage), several unexpected observations suggest that specific surveillance of the population with mild hemophilia is warranted. In addition to the high incidence of HCV in the older cohorts of mild hemophilia patients, the incidence of overweight/obesity was greater in the mild cohorts (Era A and B) than in the corresponding severe hemophilia cohorts. Additionally, individuals with mild hemophilia in Eras A, B, and C were more than twice as likely to be uninsured as the corresponding severe hemophilia groups. Finally, although most individuals with mild hemophilia reported two or fewer joint hemorrhages per 6 months, half of those who did experience joint bleeding reported at least five or more bleeds per
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Although beyond the scope of this analysis, more specific and/or sensitive surveillance tools are needed to understand the impact of hemophilia on the subset of mildly deficiency patients who nevertheless have relatively poor health care access or relatively poor outcomes.
Although this data set contains the largest number of men with severe hemophilia in any single registry, several limitations apply to this analysis. An inherent limitation to study interpretation is that this is a survival cohort in which patients had to survive to 1998 to be included. As a result of evaluating only survivors, it is probable that the captured outcome measures underestimate the adverse outcomes in severe disease and in the older eras, in particular. Interpretation of some data is limited by lack of historical data (e.g. has the patient ever had an inhibitor in the past) and/or detailed treatment data (e.g., details of primary versus secondary prophylaxis approaches). The laboratory data that established the severity was reported by the HTC and not determined centrally and patients could be misclassified. The recorded frequency of hemorrhages relied primarily on patient self-report, introducing potential recall bias. It is estimated that 30% of U.S. residents with hemophilia obtain care outside of the network of federally supported HTCs 26 , due to preference or insurance restrictions, and the findings of this analysis cannot necessarily be generalized to these individuals.
The prospectively collected data from 7500 adults with severe and mild hemophilia, when examined taking into account experiential differences dictated by evolving Eras of treatment and healthcare delivery, indicate that some but not all of the with each subsequently younger Era; and 5) eradicating active HCV is an immediate imperative if morbidity and mortality are to be reduced. If the surveillance data had been examined aggregating men of all ages and severities rather than using the Eras framework, some potential areas that deserve prospective focus might have been less obvious. Of particular concern is that the youngest Era of men with hemophilia continues to be at risk for morbidity due to excessive bleeding, to a high proportion of uninsured men, and to population demographics that include an increasingly diverse racial/ethnic makeup that may be associated with higher risk for inhibitors and their complications. The use of mild hemophilia as a comparison group also revealed a subgroup of individuals with mild hemophilia who experience worse bleeding outcomes and are otherwise not well characterized. Surveillance specifically tailored to examine non-severe hemophilia may be revealing. The UDC experience demonstrates that national surveillance in the US hemophilia population remains vital to inform improvements in HTC access, therapeutics and outcomes.
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The The assays required to determine specific diagnosis and degree of deficiency were not available in childhood for most men in this cohort, who were diagnosed based on bleeding severity and non-specific assays. During early childhood and musculoskeletal development, plasma but not clotting factor replacement was available. Men in this cohort had neither access to specialized HTC clinical care nor home-based therapy during childhood. B 1958-1975 During this transitional era, accurate laboratory diagnosis and treatment with cryoprecipitate or clotting factor VIII concentrate gradually became available during childhood, but only in a limited number of bleeding disorder clinics primarily located in academic, urban hospitals. 28 Factor IX concentrates were unavailable during childhood for most in this birth cohort. Congress enacted the law establishing the first HTCs in 1975.
Era
Era C 1976-1982
Accurate laboratory diagnosis and effective plasma-derived hemostatic agents became more widely available beginning in early childhood. Hemostatic agents for individuals with inhibitors were introduced. The innovation of teaching patients/families to administer factor concentrate in the home [29] [30] [31] for prompt on demand bleeding treatment was increasingly implemented at specialty hemophilia clinics. The number of HTCs grew, primarily in large urban areas. Nevertheless, treatment with factor concentrates resulted in exposure to the Hepatitis B (HBV) and C (HCV) viruses and HIV during this period.
Era D 1982-1993
The men in this cohort had access to virally-inactivated clotting factor concentrates (and subsequently recombinant factor) available throughout most of childhood. Simultaneously, HTCs expanded in number and geographic reach through federally mandated regionalization, and national systems for surveillance of blood safety were established. Therapy was prescribed through the growing system of coordinated regional comprehensive HTCs. Home therapy was accepted as standard of care for all ages. 32, 33 Prophylactic clotting factor replacement was recommended as the standard of care for children in the US, although widespread adoption of primary prophylaxis was slow during the time this group of men were children. 
